Evidence map›Paper›PMID 36407819›Full record

ArticleVaccine: X2022

COVID-19 vaccination in Africa: A case of unsatisfied expectation and ill-preparedness.

Osmond C Ekwebelem, Phemelo Tamasiga, Abdullahi Tunde Aborode, Ismaeel Yunusa, Uju Nwauzoma, Helen Onyeaka

Abstract read
In one paragraph

Article in Vaccine: X, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Global vaccine development.Nature medicine · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Osmond C EkwebelemFaculty of Biological Sciences, University of Nigeria, Nsukka, Nigeria.
Phemelo TamasigaAm Depenbrock 8, 33332 Gütersloh, Germany.
Abdullahi Tunde AborodeHealthy Africans Platform, Research and Development, Ibadan, Nigeria.
Ismaeel YunusaDepartment of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC, USA.
Uju NwauzomaFaculty of Environmental Studies University of Nigeria, Enugu Campus, Nigeria.
Helen OnyeakaSchool of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With a population of 1.3 billion people, of which 56% reside in rural settings, Africa seemed ill-prepared to handle the distribution of a COVID-19 vaccine. In addition, the capacity needed for a successful COVID-19 vaccination campaign in Africa surpassed the available resources in local and state health agencies. As a result, African governments were advised to coordinate resources, health officials, and vaccinators, including local health practitioners, medical technicians, and pharmacists for the largest-ever vaccination campaign in Africa. Although the rolling out of the SARS-COV-2 vaccine was, as expected, slow in many African countries, and not yet enough to cover the entire population in Africa, the mass vaccination campaign in Africa must continue to ensure that priority for vaccination is extended beyond front-liners (healthcare workers) and specific high-risk populations, which has largely been the case in some African countries. This article highlights the overarching areas that we believe need to be prioritized to enhance Africa's effectiveness and coverage in the mass COVID-19 vaccination program.

Indexed as

AfricaCOVAXCOVID-19 vaccinationCOVID-19 vaccineVaccination

Identifiers

PMID36407819
PMCPMC9643322

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.